🇺🇸 FDA
Pipeline program

Idefirix 11 mg powder for concentrate for solution for infusion, Delandistrogene moxeparvovec-rokl

SRP-9001-104

Phase 1 small_molecule active

Quick answer

Idefirix 11 mg powder for concentrate for solution for infusion, Delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy (DMD) is a Phase 1 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Sarepta Therapeutics
Indication
Duchenne muscular dystrophy (DMD)
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials